Business
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates Shionogi gets access to BioVersys’ proprietary ansamycin platform and the BV500 program BioVersys eligible to receive upfront and near-term research payments of CHF 5.0 million and, upon exercise of the lic
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) --","length":53,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates ","length":196,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":196,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Shionogi gets access to BioVersys’ proprietary ansamycin platform and the BV500 program ","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"BioVersys eligible to receive upfront and near-term research payments of CHF 5.0 million and, upon exercise of the license option, regulatory and sales milestones of up to CHF 479 million as well as royalties on future sales","length":229,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":316,"olType":false},{"type":"text","content":"BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi & Co., Ltd., to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates.","length":467,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, BioVersys will receive an upfront payment and near-term research payments totaling CHF 5.0 million. Once clinical candidates have been selected, Shionogi may exercise a license option for which BioVersys would b...